This article was originally published in The Gray Sheet
510(k) is filed for the non-invasive bilirubin analyzer, which the company claims provides comparable results to blood tests in less than a minute by shining and analyzing light beams on an infant's forehead. Launched overseas in May, the product was cleared in Canada on June 29 ("The Gray Sheet" July 13, In Brief)
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.